HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review

The approval of CDK4/6 inhibitors has dramatically improved care for the treatment of HR+/HER2– advanced breast cancer, but navigating the rapidly-expanding treatment evidence base is challenging. In this narrative review, we provide best-practice recommendations for the first-line treatment of HR+/...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Katarzyna J. Jerzak, Nathaniel Bouganim, Christine Brezden-Masley, Scott Edwards, Karen Gelmon, Jan-Willem Henning, John F. Hilton, Sandeep Sehdev
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	MDPI AG 2023-06-01
Cyfres:	Current Oncology
Pynciau:	advanced breast cancer CDK4/6 inhibitors HR+/HER2– mutational testing treatment considerations
Mynediad Ar-lein:	https://www.mdpi.com/1718-7729/30/6/411
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!